Quantum Biopharma (QNTM) Liabilities and Shareholders Equity (2021 - 2026)

Quantum Biopharma has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $14.9 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $14.9 million, changed 0.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $55.5 million (down 16.19% YoY), and the FY2025 annual result was $11.2 million, down 34.8% from the prior year.
• Liabilities and Shareholders Equity came in at $14.9 million for Q1 2026 at Quantum Biopharma, up from $11.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $38.4 million in Q4 2022 to a low of $11.2 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $15.3 million (2024), against an average of $17.8 million.
• Across the five-year window, Liabilities and Shareholders Equity slumped 54.51% in 2023 and climbed 0.35% in 2026, its largest moves.
• Quantum Biopharma's Liabilities and Shareholders Equity stood at $38.4 million in 2022, then plunged by 54.51% to $17.5 million in 2023, then slipped by 2.03% to $17.1 million in 2024, then slumped by 34.8% to $11.2 million in 2025, then jumped by 33.74% to $14.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $14.9 million (Q1 2026), $11.2 million (Q4 2025), and $14.2 million (Q3 2025), per Business Quant data.